Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cocrystal Pharma Expects To Initiate CDI-988 Phase 1b Norovirus Challenge Study In Q1 2026

Author: Benzinga Newsdesk | November 14, 2025 08:29am
  • Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatment
  • Expects to initiate CDI-988 Phase 1b norovirus challenge study in Q1 2026
  • Granted NIH SBIR award to advance influenza A/B replication inhibitor program

BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and nine months ended September 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities.

Posted In: COCP


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist